Transphorm, Inc (TGAN) Reports In-Line Q3 EPS

Transphorm, Inc (OTC: TGAN) reported Q3 EPS of ($0.09), in-line with the analyst estimate of ($0.09). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $4 million.

For earnings history and earnings-related data on Transphorm, Inc (TGAN) click here.

You May Also Be Interested In

• ASML Holdings (ASML) Tops Q2 EPS by 59c; offers guidance
• Kestra Medical Technologies, Ltd. (KMTS) Misses Q2 EPS by 9c, Beats on Revenue
• Phoenix Education Partners, Inc. (PXED) Misses Q3 EPS by 14c; Offers Outlook